BioCryst Pharma Gout Treatment Meets Study Goals; Shares Up - Wall Street Journal

BioCryst Pharma Gout Treatment Meets Study Goals; Shares Up Wall Street Journal BioCryst Pharmaceuticals Inc. (BCRX) said its treatment for gout in combination with a traditional medicine for the disease reached its primary endpoints in a recent study. The drug developer's shares were up 12.6% at .95 in recent premarket trading. ... BioCryst says gout drug worked in mid-stage trialForbes BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study ...MarketWatch (press release) BioCryst shares surge on positive IIb study for gout drugFierceBiotech MedCity News -TheStreet.com all 41 news articles »

Savient Stock Hits New 52-Week Low (SVNT) - TheStreet.com

Savient Stock Hits New 52-Week Low (SVNT) TheStreet.com The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. Practice your SVNT trading strategies and win cash in our stock game. TheStreet Ratings rates Savient as a sell. ... and more »

Arthritis needn't be a pain - ScrippsNews

Arthritis needn't be a pain ScrippsNews “There are 100 different types of arthritis, and the treatment varies for each.” White says the most common forms of arthritis include osteoarthritis, which affects 27 million Americans; gout, which affects 8.1 million and rheumatoid arthritis, ... and more »

Novartis's Ilaris Helps Children With Form of Arthritis in Study - Bloomberg

Reuters

Novartis's Ilaris Helps Children With Form of Arthritis in Study Bloomberg Novartis AG (NOVN)'s Ilaris, rejected by a US advisory panel in June as a treatment for gout, helped children with a rare form of arthritis in a late-stage study. Ilaris improved symptoms of systemic ... Novartis' canakinumab shows promise in SJIAPharma Times Novartis AG New Drug May Provide Relief for Juvenile Arthritisallvoices Novartis drug helps in serious childhood arthritisReuters all 52 news articles »